Verification of the Pharmaceutical Spending Ceiling (7.96% of the national health requirement)
The net approved pharmaceutical expenditure borne by the NHS in the period January-May 2017 calculated net of discounts, total sharing (regional tickets and sharing of the reference price) and the 1.83% pay-back paid to the Regions by pharmaceutical companies, was amounted to €3,528 million, showing an increase of € +31 million (+0.7%) compared to the previous year.
Consumption, expressed in number of recipes (250 million recipes), shows a decrease of -0.6% compared to 2016, while the incidence of tickets decreases by -1.0% (-7.0 million euro). At the same time, an increase of +3.4% (+362.3 million daily doses) was observed in the daily doses dispensed [excerpt]
The absolute variance is over 740 million euros compared to the new expenditure ceilings, those established by the latest budget law (of article 1, paragraphs 400 and 401 of Law 232/16.). The data is present in the latest monitoring form made available by the Italian Medicines Agency for the period January-May 2017 (read here ).
This means - making a linear projection - that at the end of 2017 the overrun could be even higher than that recorded in 2016 which was over 1.5 billion euro.
Full document: AIFA. Monitoring of National and Regional Pharmaceutical Expenditure January-May 2017
Pharmaceutical expenditure: change of 741 million in the first 5 months of the year
